A new class of cell cycle inhibitors is currently entering clinical trials. These drugs exert their activity by inhibition of cyclindependent kinases (cdk) and induce cell cycle arrest and apoptosis in cancer cells. Roscovitine, a cdk2-inhibitor that is in preclinical evaluation, induced apoptosis in B-CLL cells at doses that were not cytotoxic for normal human B cells. At 20 lM, Roscovitine induced apoptosis in 21 of 28 B-CLL samples and was equally effective in zap-70-positive or -negative samples. Caspase-3 was cleaved in B-CLL cells exposed to Roscovitine and the pancaspase inhibitor z.VAD.fmk-blocked Roscovitine-induced apoptosis. Expression of the proapoptotic protein Bak was increased and Bax cleavage and conformational change was observed in Roscovitine-treated B-CLL cells. Antiapoptotic proteins Mcl-1 and XIAP were downregulated, but the expression of Bcl-2 remained unchanged. In contrast to previous reports in cancer cell lines, Roscovitine treatment was not accompanied by nuclear accumulation of p53. Cyc202 (R-Roscovitine) is in early clinical trials in cancer patients. Given its powerful effects on zap-70-positive and -negative B-CLL cells, but not on normal lymphocytes, Roscovitine might be an attractive drug to be tested in this incurable disease.
Introduction
Chronic lymphocytic leukemia is the most frequent leukemia in the Western world, accounting for an estimated 8100 new cases annually in the United States. 1 Accumulation of CD5 þ mature B-lymphocytes seems to be caused by defective programmed cell death, although a proliferating pool of cells might contribute to disease progression. 2, 3 Chemotherapy with alkylating agents, nucleoside analogues or monoclonal antibodies (mAb) can induce remissions in CLL, but few patients are cured even with high-dose chemotherapy and stem cell support. [4] [5] [6] B-CLL cells are characterized by high expression of a variety of antiapoptotic proteins. 7 Although the underlying defect in apoptosis remains undefined, antiapoptotic molecules of the Bcl-2 family including BCL-2 and MCL-1 seem to be involved. 8, 9 Higher levels of the antiapoptotic protein MCL-1 7 and increased ratios of Bcl-2 or Mcl-1 relative to the proapoptotic antagonist Bax have been correlated with refractory disease. 10, 11 Recently, it has been recognized that B-CLL consists of at least two different biologic subgroups, characterized by the presence or absence of somatic mutations in specific immunoglobulin heavy-chain variable region genes. 12 With the use of comparative gene expression profiling, the tyrosine kinase zap-70 has been found to be selectively expressed in the unmutated group with a poor outcome 13 and has been identified as a powerful prognostic factor. 14 New drugs should therefore be tested in both biological subgroups.
In the peripheral blood, B-CLL cells express high levels of the cyclin-dependent kinase (cdk) inhibitor p27 and are arrested in the G0 phase of the cell cycle.
15 Surprisingly, these resting cells have been shown to be susceptible to Flavopiridol, a cell cycle inhibitor, although Flavopiridol was equally cytotoxic towards normal human lymphocytes. 16 Flavopiridol and 7-hydroxystaurosporine induced apoptosis and downregulated antiapoptotic proteins in B-CLL cells. 17 Clinical trials of Flavopiridol in B-CLL are currently ongoing and modest activity as a single agent has been reported in mantle-cell lymphoma. 18 Roscovitine is a purine analog that competes with ATP for its binding site on CDKs 19, 20 and has demonstrated antitumor activity in a variety of cancer cell lines. 21, 22 While Roscovitine is quite specific for cdk2 inhibition at doses up to 10 mM, effects on other kinases (like cdk 1 and cdk7) have also been shown. 23 It has been reported that Roscovitine does not only cause cell cycle arrest but also apoptosis in cancer cells, 21, 22 and the induction of cell death occurred from all compartments of the cell cycle. 24 Nuclear accumulation of p53 was reported to be involved in apoptosis induction, although the precise mechanism remains to be determined. 25, 26 Recently, Cyc202 (R-Roscovitine) has been demonstrated to be highly effective in a panel of 19 human tumor cell lines and a human tumor xenograft model. This drug is currently entering clinical phase I studies. 24 In the present study, we have demonstrated that Roscovitine induced apoptosis in a dose-dependent manner in B-CLL cells that was accompanied by caspase activation and modulation of Bcl-2 family proteins. Importantly, Roscovitine was not capable of inducing cell death in normal mononuclear cells or B cells at doses that were toxic for B-CLL cells. Therefore, our results suggest a possible therapeutic role for Roscovitine in the treatment of patients with B-CLL.
Materials and methods

Cell samples
After informed consent, peripheral blood was obtained from patients with a diagnosis of B-CLL according to clinical and immunophenotypic criteria. Patients were either untreated or had not received chemotherapy for a period of at least 2 months prior to investigation. At the time of analysis, all patients were clinically stable, free from infectious complications and undergoing routine clinical outpatient review. Cells were immediately purified as described below and either cultured or carefully frozen using standard procedures. Frozen samples were used after careful thawing and after Ficoll-Hypaque (Biochrom, Berlin, Germany) density-gradient centrifugation, resulting in a viability of more than 95%.
Reagents and antibodies
Ab specific for Bax, Bak and retinoblastoma (RB) were purchased from BD-Pharmingen (San Diego, CA, USA); MCL-1 and p53 were from Santa Cruz Biotechnology (CA, USA); XIAP, Bcl-2 and zap-70 were from BD Biosciences Transduction lab (San Diego, CA, USA); and mAb specific for actin was obtained from Sigma (Deisenhofen, Germany). Mouse monoclonal anti-Bax antibody (clone YTH-6A7) was from Trevigen, Gaithersburg, MD, USA). Roscovitine was obtained from Sigma. The pancaspase inhibitor zVAD.fmk was purchased from Calbiochem (Schwalbach, Germany).
Separation procedures
Enrichment of B-CLL cells by density-gradient centrifugation over a Ficoll-Hypaque layer (Biochrom, Berlin, Germany) and immunomagnetic depletion of T-lymphocytes and monocytes has been described. 27 Peripheral blood mononuclear cells (PBMNC) from normal controls were used after Ficoll-Hypaque density-gradient centrifugation without further separation procedures. B cells from normal controls were separated by positive selection using CD19-coated magnetic beads (Dynal Biotech, Oslo, Norway) and Detachabead (Dynal) according to the manufacturer's instructions to a purity of greater than 97%.
Culture conditions
Purified leukemic B cells, B cells from normal controls or PBMNC were cultured in RPMI 1640 medium (Biochrom) supplemented with 10% fetal calf serum (Biochrom), penicillin/ streptomycin 50 IU/ml, Na-pyruvate 1 mM, L-glutamine 2 mM, L-asparagine 20 mg/ml, 2-mercaptoethanol 0.05 mM, HEPES 10 mM and MEM nonessential amino acids 0.7 Â (Biochrom) at 371C and 5% CO 2 in a fully humidified atmosphere.
Analysis of fragmented DNA and of membrane flipping
The amount of fragmented DNA was assessed by a TdTmediated dUTP nick-end labeling (TUNEL) assay as reported. 28 Incorporation of fluorescein-labeled dUTP into DNA strand breaks was detected by flow cytometry. Exposure of phosphatidylserine (PS) on the outside of the plasma membrane was analyzed by flow cytometry as described. 28 In brief, cells were stained with FITC-labeled mAbs to Annexin V, and counterstained with propidium iodide (PI). The numbers of viable cells (VC), identified as being negative for both Annexin and PI, varied from one sample to another due to spontaneous apoptosis in culture.
Investigation of mitochondrial membrane potential
The mitochondrial membrane potential, DC m , was studied by flow cytometric analysis of the fluorescence of 3,3 0 -dihexyloxacarbocyanine iodide (DiOC6(3)) as reported. 28 
Analysis of caspase-3 activity
Cells were fixed and permeabilized using Fix and Perm kit (Caltag, Burlingame, CA, USA) for 15 min at room temperature. Activated caspase-3 was detected by flow cytometry with an FITC-conjugated mAb that fails to recognize the inactive enzyme (clone C92-605, BD Biosciences, San Diego, CA, USA).
Immunoblotting
A total of 2-4 Â 10 7 cells were lysed as described previously 28 in lysis buffer (10 mM Tris-HCl (pH 7.4), 5 mM EDTA, 130 mM NaCl, 1% Triton, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 and 10 mg/ml of each phenantroline, aprotinin, leupeptin and pepstatin) for 20 min at 41C. Lysates were spun at 12 000 rpm for 20 min and the supernatant was collected. Protein concentration was assessed by the Bio-Rad assay method (Bio-Rad Laboratories, Munich, Germany). Total extracts (50 mg/lane) were subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and blotting was performed on PVDF membranes (Immobilon-P, Millipore GmbH. Bedford, MA, USA). Blots were developed using SuperSignal s chemoluminescent substrates from Pierce Chemical Company (KMF GmbH, St Augustin, Germany).
For determination of zap-70 expression, Western blots included total cellular extracts from a mantle cell lymphoma cell line (NCEB) and a T-cell lymphoma line (Jurkat) as a negative and positive control, respectively.
Detection of nuclear accumulation of p53
Cytosolic and nuclear protein fractions were prepared as described elsewhere. 29 In brief, cells were lysed in lysis buffer (150 mM HEPES, pH 7.9, 150 mM KCl, 150 mM sucrose, 150 mM MgCl 2 , 150 mM DTT, NP-40 0.15%, 15 mM PMSF and 10 mg/ml of each phenantroline, aprotinin, leupeptin and pepstatin) and spun at 13 200 rpm for 5 s. Protein concentration of the supernatant containing cytosolic proteins was determined and subjected to 7.5% SDS-PAGE. The nuclear pellet was resolved in a buffer containing glycerol and sonicated. Protein concentration of the supernatant containing nuclear proteins was determined and Western blots were performed using 20 mg of protein/per lane.
Mutational analysis of the p53 gene
Mutational analysis of the p53 gene was performed as described previously. 30 The highly conserved exons 5-8 of p53, including the intron/exon boundaries, were amplified by PCR. The quality and correct size of the PCR products were checked on agarose gels. Prior to sequencing, the PCR products were purified using the Quiaquick PCR Purification Kit (Quiagen).
Automated fluorescent sequencing in both directions was performed with the BigDye Terminator Cycle Sequencing kit (PE Applied Biosystems, Foster City, CA, USA) in an ABI Prism 377 automated sequencer (PE Applied Biosystems). Comparison with the germline sequences was performed with DNASIS 2.6 software (Hitachi Engineering).
Results
Roscovitine induces apoptosis in B-CLL cells in a dose-dependent manner
The effect of Roscovitine was investigated in purified B-CLL cells. Viability was determined after 24 h in vitro culture using the Annexin-V/PI assay as described in Materials and methods. One representative Annexin-V/PI stain of B-CLL cells cultured in medium alone or in the presence of increasing doses of Roscovitine is shown in Figure 1a . Figure 1b shows the mean7s.e.m. (standard error of the mean) of VCs of 17 independent samples cultured in medium or Roscovitine, as indicated. Although Roscovitine significantly reduced the amount of VCs at 10 mM, the effect was much more pronounced at doses of 20 mM with less than 10% VCs in most samples when cells were treated with Roscovitine 50 mM. Control experiments demonstrated that the amount of DMSO needed to dissolve Roscovitine did not induce apoptosis in B-CLL cells (data not shown).
Roscovitine toxicity in PBMNC and normal B cells
In contrast to B-CLL cells, apoptosis was not induced in PBMNC cultured in the presence of 10 mM Roscovitine and only minor effects on cell viability were observed in the presence of 20 mM Roscovitine. However, profound induction of cell death was detected in the presence of the highest concentration. One representative experiment out of three performed is depicted in Figure 2a . To further compare whether normal B cells were as sensitive towards Roscovitine treatment as B-CLL cells, we cultured highly purified B cells with Roscovitine at the indicated concentrations. Similar to PBMNC, only minor effects were observed with Roscovitine at 10 or 20 mM, but cell death was strongly induced in the presence of Roscovitine at 50 mM. One experiment is shown in Figure 2b with similar results in two additional samples. To rule out that differences between normal B cell and B-CLL cells were caused by differences in the separation method (positive and negative separation, respectively), we performed Annexin-V/PI assays in positively and negatively separated B-CLL cells and found no differences in apoptosis induction (data not shown).
Roscovitine selectively kills B-CLL cells at 20 mM: no correlation with zap-70 expression
We analyzed the effect of Roscovitine at 20 mM in a total of 28 patient samples. Apoptosis was potently induced in 21 of 28 samples tested, while the response was only moderate in the remaining seven samples (o20% absolute reduction in VCs) ( Table 1 ). All but three samples were cultured immediately after purification. The remaining samples were used after careful thawing and Ficoll-Hypaque density-gradient centrifugation. Additional experiments confirmed that Roscovitine was equally effective in fresh and frozen cells from individual samples (data not shown). Importantly, the difference between apoptosis induction (% absolute reduction) in B-CLL cells was significantly different (P ¼ 0.003) from apoptosis induction in nine different PBMNC samples, demonstrating that Roscovitine at 20 mM selectively kills B-CLL cells (Figure 3) .
B-CLL cells consist of at least two subgroups with different biology and prognosis, which can be easily separated by expression of the tyrosine kinase zap-70. Age, gender, Binet stage, number of previous therapies, zap-70 expression and viability after 24 h of culture in medium (V medium) and Roscovitine (V Ros) of 28 independent patient samples are shown. ND ¼ not done. All samples were cultured immediately in medium alone or in the presence of Roscovitine at 20 mmol for 24 h after completion of the separation procedure, except samples #4, #13 and #20 which have been frozen and treated as described in the Materials and methods section before in vitro culture.
Induction of apoptosis by Roscovitine is caspase dependent
Cell death in B-CLL cells might be executed by different mechanisms. To investigate whether Roscovitine-induced cell death was dependent on caspase activity, we cultured B-CLL cells for 24 h with or without Roscovitine 20 mM in the presence or absence of the pancaspase inhibitor zVAD.fmk. Treatment with zVAD.fmk resulted in a small increase in VCs in cells cultured in medium alone. Inhibition of caspase activity resulted in a complete disappearance of DNA strand brakes in a TUNEL assay. Caspase-3 cleavage, which occurred to a small extent in medium cultured cells, was also inhibited ( Figure 5 ). Treatment with Roscovitine resulted in a decrease of VCs, which was accompanied by a loss in the mitochondrial membrane potential. In addition, DNA fragmentation and active caspase-3 strongly increased upon treatment with Roscovitine. Cotreatment with zVAD.fmk prevented PS externalization, DNA fragmentation and appearance of active caspase-3. The mitochondrial membrane potential was partially restored in the presence of zVAD.fmk, suggesting that caspase-dependent and -independent pathways are involved in the perturbation of mitochondria ( Figure 5 ).
Roscovitine modulates expression of pro-and antiapoptotic proteins without evidence of increased nuclear accumulation of p53
Western blot analyses were performed in total cellular lysates of purified B-CLL cells cultured for 24 and 48 h with or without Roscovitine 20 mM. The antiapoptotic protein MCL-1 was downregulated in cells cultured in medium alone as compared to MCL-1 expression in freshly isolated B-CLL cells. However, the expression of MCL-1 was further reduced in the presence of Roscovitine, and MCL-1 was no longer detectable after 48 h of culture. While the expression of bcl-2 remained unchanged, XIAP was also downregulated in response to Roscovitine. Expression of the antiapototic proteins bcl-xl and survivin was not analyzed because these proteins are not expressed in resting B-CLL cells. 31, 7 Bak and Bax are proapoptotic members of the Bcl-2 family and the expression of Bak was increased in Roscovitine-treated cells, while the expression of full-length Bax remained unchanged. However, an 18 kDa cleavage product of Bax became detectable in Roscovitine-treated cells. Staining with mAk specific for actin confirmed that the observed differences in protein expression were not due to differences in the amount of protein per lane. The results of one experiment are shown in Figure 6a , and similar results were obtained in an additional patient sample. Intracellular flow cytometry with a Bax antibody directed against the NH2-terminal region of Bax (clone YTH-6A7) was performed to detect Bax conformational changes. This region is not available for binding by Bax NH2-terminal epitope-specific antibodies in intact cells. A strong increase of fluorescence intensity was noted in Roscovitine-treated cells as compared to medium controls. Figure 6b shows one experiment, and similar results were obtained in an independent sample.
To analyze whether Roscovitine induced nuclear accumulation of p53 in B-CLL cells, cytosolic and nuclear fractions of proteins were prepared as described in Materials and methods. Western blotting revealed that p53 showed a nuclear accumulation in B-CLL cells cultured in medium alone that was not increased in the presence of Roscovitine. Successful separation of nuclear and cytosolic protein fractions was confirmed by staining with mAK against the RB protein ( Figure 7) . A mutational analysis of the p53 gene demonstrated the presence of wild-type p53 in the sample shown. One additional experiment gave similar results.
Discussion
Cyclin-dependent kinase inhibitors are a new class of anticancer agents that are extensively analyzed in vitro and are in early clinical trials in patients with non-Hodgkin's lymphoma. 32, 33 Although B-CLL is characterized by the accumulation of small resting malignant B cells in the peripheral blood, two cdk inhibitors, Flavopiridol and UCN-01, have been shown to induce apoptosis in vitro in these G0 arrested cells. 16, 17 The relevance of these findings has been questioned because Flavopiridol was equally cytotoxic towards mononuclear cells from normal controls. 16 Roscovitine, an olomoucine-related purine has been developed as a cdk inhibitor that competes with ATP for its binding site on CDKs. 19, 20 While Roscovitine was thought to inhibit cdk (especially cdk2) activity specifically, Roscovitine treatment was not only accompanied by cell cycle blockade but also induced apoptosis from all compartments of the cell cycle in different tumor models. 24, 26 In our present study, we show for the first time that the cdk inhibitor Roscovitine induces apoptosis in B-CLL cells in a dosedependent manner. Importantly, Roscovitine was much more cytotoxic at 20 mM in B-CLL cells than in mononuclear cells from normal donors (Figure 3) . It is important from a clinical point of view that Roscovitine was equally effective in B-CLL cells expressing the tyrosine kinase zap-70, which is a powerful prognostic factor and separates two biologically distinct disease entities, 14 and in zap-70 negative cells (Figure 4 ). Experiments with purified normal B cells demonstrated that this was not a B-cell-specific effect as the B-cell viability of control cells was only reduced in the presence of 50 mM Roscovitine.
Cell death in response to chemotherapeutic agents usually involves the mitochondrial pathway, which is associated with a permanent loss of the mitochondrial membrane potential. The Figure 5 Roscovitine-induced apoptosis in B-CLL cells involves loss of the mitochondrial membrane potential and caspase activation. CLL cells were cultured for 24 h in the presence of Roscovtine 20 mM or medium with or without the pancaspase inhibitor zVAD.fmk. After staining with fluorescent compounds, cells were analyzed by flow cytometry. Cells were stained for Annexin V and PI and DNA strand breaks were assessed with a TUNEL assay. For analysis of the mitochondrial membrane potential DC m , cells were incubated with DiOC6(3) for 30 min. Intracytoplasmatic staining with an mAb against active caspase-3 was performed. The results from one representative experiment B-CLL are displayed. One additional experiment gave similar results.
release of proapoptotic factors activates effector caspases, which cause DNA fragmentation and apoptosis. 34 However, caspaseindependent cell death has also been described in different tumor models and B-CLL. [34] [35] [36] Inhibition of caspase activity using the pancaspase inhibitor zVAD.fmk inhibited Roscovitineinduced DNA fragmentation, cleavage of caspase-3 and restored viability to baseline values, suggesting that Roscovitine-induced cell death depends on caspase activity. Roscovitine-induced apoptosis was also associated with a loss of the mitochondrial membrane potential, which was only partially restored upon treatment with the caspase inhibitor. These data indicate that the loss of the mitochondrial membrane potential was at least in part independent of caspase activity ( Figure 5 ).
BCL-2 family proteins play a central role in controlling the mitochondrial pathway. 37 The antiapoptotic proteins BCL-2 and MCL-1 have been implicated in B-CLL pathophysiology, 8, 9 and high expression seems to be associated with chemotherapy resistance. 10, 11 While Bcl-2 levels remained unchanged in Roscovitine-treated cells, MCL-1 expression was markedly reduced. Similar results were reported in B-CLL cells and myeloma cells that were exposed to the cdk inhibitors UCN01 and Flavopiridol. 17, 38 While expression levels of the proapoptotic BCL-2 family members Bax and Bak were not altered in Flavopiridol-treated cells, 17 treatment with Roscovitine resulted in increased expression of Bak and the appearance of a prominent 18 kDa cleavage product of Bax ( Figure 6 ). The appearance of an 18 kDa Bax product has been reported previously in apoptotic B-CLL cells 10, 28 and has been demonstrated to be more potent in apoptosis induction than p21 Bax. 39 The presence of either Bax or Bak seems to be essential for apoptosis in most cell types. 40 Although both proteins are transcriptionally regulated, Bax and Bak are stringently controlled at the post-translational level and conformational changes have been reported to be necessary for apoptosis induction in experimental systems and B-CLL cells. [41] [42] [43] [44] Bax translocation to the mitochondrial membrane involves a conformational change that exposes the NH2 terminus and the hydrophobic COOH terminus. 41 The potency of Roscovitine to induce apoptosis in B-CLL cells might be further enhanced by its ability to downregulate XIAP expression as XIAP is a member of the inhibitors of caspase (IAP) family of proteins that inhibit the activity of executioner caspases. 34 Taken together, the effect of Roscovitine closely resembles the effect of Flavopiridol and UCN-01 with respect to MCL-1 and Roscovitine modulates the expression and conformation of pro-and antiapoptotic proteins. (a) Purified B-CLL cells were cultured in the presence or absence of Roscovitine at 20 mM for 24 and 48 h, respectively. MCL-1 was revealed by immunoblotting with mAb in total cell lysates (50 mM). The same membrane was sequentially stripped and probed with anti-XIAP, anti-Bcl-2, anti-Bak and anti-Bax. Protein concentrations were normalized by the Bio-Rad assay method and blots were reprobed with antiactin antibody to control for equal protein loading. In two independent experiments, intracellular FACS staining was performed with the conformation-specific Bax antibody YTH-6A7 (shaded histogram) and a corresponding isotype control. One experiment is shown in (b); the other one gave very similar results. Roscovitine treatment does not result in nuclear p53 accumulation. Nuclear (n) and cytosolic (c) protein fractions were prepared as described in Materials and methods. P53 was revealed by immunoblotting. The same membrane was sequentially stripped and reprobed with RB antibody to control for the successful separation of nuclear and cytosolic fractions, respectively. Cells were cultured in medium alone (a) or in Roscovitine at 20 mM (b).
XIAP expression, and also affects the expression and conformation of the proapoptotic Bcl-2 family members Bax and Bak ( Figure 6 ). As has been reported in Flavopiridol-treated B-CLL cells, Roscovitine-induced apoptosis was not dependent on nuclear p53 accumulation 16 ( Figure 7 ). Although cdk2 is expressed in resting B-CLL cells, no activity has been observed in in vitro kinase assays, making it unlikely that inhibition of cdk2 contributes to the observed effects in resting B-CLL cells. 31 However, cdks are not the only targets of cdk inhibitors and interference with the mitogen activated protein (MAP)-kinase pathway has been recently reported in colon carcinoma cell lines treated with Roscovitine. 45, 46 Cyc202 (R-Roscovitine) is currently in clinical phase I trials. It is readily orally bioavailable and high plasma levels in the range 10-20 mM have been achieved with a well-tolerated dose of 2500 mg/day for 5 day q3 weeks. Vomiting, hypokalemia and skin rash were the doselimiting toxicities at higher doses with no signs of significant hematotoxicity (Pierga JY et al. Proc of Am Soc Clin Oncol 2003; 22: 210 (abstract 840)).
B-CLL is still an incurable disease and new therapeutic strategies are needed. Roscovitine is an attractive candidate drug, given its potency to induce apoptosis in B-CLL cells but not in normal leukocytes. Further in vitro studies will deal with the effect of combination schedules of chemotherapeutic agents and Roscovitine on B-CLL cells.
